Evercrisp Biosciences, Inc. has filed for Chapter 11 process to reorganize its rising debts. The biotech research company is backed by Apple Tree Partners (ATP), a life sciences-focused investment firm. ATP’s portfolio also includes Red Queen Therapeutics, which filed for Chapter 11 bankruptcy in December 2025.
Evercrisp Biosciences Files for Chapter 11 in Delaware
Evercrisp Biosciences, Inc. submitted a voluntary petition in bankruptcy court, according to filings on PACER. The filing was made on January 1, 2026, in the U.S. Bankruptcy Court for the District of Delaware.
Attorney L. Katherine Good of Potter Anderson & Corroon LLP is representing the company. Meenu Chhabra Karson, the CEO of Evercrisp Biosciences, Inc., signed the petition before its submission.
As the proceedings continue in the court, Evercrisp Biosciences, Inc. is planning to continue operations as normal.
Company Background
Evercrisp Biosciences, Inc. uses proprietary technologies to design miniproteins that can access kidney, brain, muscle, and other tissues that are difficult to access using genetic medicines. The California-based company focuses on developing technologies designed to improve the delivery of genetic therapies to hard-to-reach tissues.
A Series of Bankruptcy Filings by ATP-backed Companies
Evercrisp Biosciences, Inc. falls under the list of Apple Tree Partners’ portfolio companies. ATP bears a 25-year history as a life sciences-focused investment company. It creates and backs companies across the life cycle, from pre-IP concepts and asset spinouts to seed-stage startups through IPO and beyond.
Prior to Evercrisp Biosciences, Inc., another company backed by ATP, Red Queen Therapeutics, Inc., filed for Chapter 11 on December 15, 2025. That case is ongoing in the U.S. Bankruptcy Court for the District of Delaware as the company works on a reorganization plan.
Other than this, as per PACER, Nine Square Therapeutics, Inc. filed for Chapter 11 bankruptcy on January 1, 2026. The ATP-backed biotechnology company is seeking to restructure its debt through the court-supervised process.
Attorney L. Katherine Good of Potter Anderson & Corroon LLP is representing the company at the U.S. Bankruptcy Court for the District of Delaware through case number 1:26-bk-10001.
Latest Case Filings and Updates of Evercrisp Biosciences, Inc.
The filing details on PACER show that Judge Laurie Selber Silverstein was added to the case to handle the proceedings for Evercrisp Biosciences, Inc. on January 1, 2026. Attorney L. Katherine Good paid a fee amounting to $1,738 to file its voluntary petition.
Other crucial details of the California-based company’s bankruptcy proceedings are:
- Filing Date: January 1, 2026
- Court and Jurisdiction: U.S. Bankruptcy Court for the District of Delaware
- Type of Filing: Active, Voluntary Petition
- Chapter: 11
- Case Number: 26-10000-LSS
- Estimated Assets: $1,000,001 – $10 million
- Estimated Liabilities: $1,000,001 – $10 million
- Reason for Filing: Readjust debts under court supervision
The filing notes that Evercrisp Biosciences, Inc. currently owes around 50 to 99 creditors in total. Funds will be available for distribution to the unsecured creditors, the filing adds.
As per PACER, other than Evercrisp Biosciences, Inc., eight other affiliated entities have filed for bankruptcy. This includes ATP Life Sciences Ventures, L.P., Apertor Pharmaceuticals, Inc., and Initial Therapeutics, Inc.
A list of 20 largest unsecured creditors and corporate ownership statement were some documents submitted by attorney L. Katherine Good on behalf of Evercrisp Biosciences, Inc., the filing shows.
The latest case adds to a string of Chapter 11 filings among Apple Tree Partners-backed biotechnology companies, as Evercrisp Biosciences, Inc. moves forward with court-supervised restructuring.
